National screening programs for cervical cancer in Asian countries.
Asia
Cancer Screening
Cervical Cancer
National Health Programs
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
16
02
2020
accepted:
16
02
2020
pubmed:
9
4
2020
medline:
3
9
2021
entrez:
9
4
2020
Statut:
ppublish
Résumé
Cervical cancer is still one of the most common female cancers in Asia and the leading cause of cancer-related deaths in low- and middle-income countries. Nowadays, national screening programs for cervical cancer are widely provided in Asian countries. We reviewed the National Cancer Screening Program (NCSP) in China, India, Indonesia, Japan, Korea, and Thailand. The NCSP were established at varying times, from 1962 in Japan to 2014 in Indonesia. The primary screening method is based on cytology in all countries except for India and Indonesia. In India and Indonesia, visual inspection of the cervix with acetic acid (VIA) is mainly used as a primary screening method, and a "see and treat" strategy is applied to women with a positive VIA result. The starting age of NCSP ranges from 18 years in China to 30 years in Thailand. The screening interval is 2 years in all countries except for China and Indonesia, in which it is 3 years. Uptake rates of NCSP vary from 5.0%-59.7%. Many women in low- and middle-income countries still do not participate in NCSP. To improve uptake rates and thereby prevent more cases of cervical cancer, Asian countries should continue to promote NCSP to the public using various approaches.
Identifiants
pubmed: 32266804
pii: 31.e55
doi: 10.3802/jgo.2020.31.e55
pmc: PMC7189071
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e55Informations de copyright
Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Int J Cancer. 2005 Sep 10;116(4):617-23
pubmed: 15818610
CA Cancer J Clin. 2012 May-Jun;62(3):147-72
pubmed: 22422631
J Obstet Gynaecol Res. 2013 Jun;39(6):1190-9
pubmed: 23718197
Int J Cancer. 2019 May 1;144(9):2144-2152
pubmed: 30474210
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Obstet Gynaecol Res. 2015 Sep;41(9):1313-25
pubmed: 26014371
Int J Gynaecol Obstet. 2011 Apr;113(1):14-24
pubmed: 21257169
Obstet Gynecol. 2015 Feb;125(2):330-7
pubmed: 25569009
Cancer Res Treat. 2017 Jul;49(3):798-806
pubmed: 27857022
Eur J Cancer. 2009 Oct;45(15):2640-8
pubmed: 19695864
Cancer Res Treat. 2018 Apr;50(2):303-316
pubmed: 29566481
J Community Health. 2018 Jun;43(3):611-615
pubmed: 29302852
J Med Screen. 2006;13 Suppl 1:S39-43
pubmed: 17227641
Gynecol Oncol. 2015 Feb;136(2):178-82
pubmed: 25579107
Oncologist. 2013;18(12):1285-97
pubmed: 24217555
Cancer. 2003 Jun 15;97(12 Suppl):3133-275
pubmed: 12784323
J Gynecol Oncol. 2019 Jan;30(1):e38
pubmed: 30574686
Lancet. 2007 Aug 4;370(9585):398-406
pubmed: 17679017
Asian Pac J Cancer Prev. 2015;16(18):8541-51
pubmed: 26745114
PLoS One. 2010 Mar 09;5(3):e9584
pubmed: 20231893
Asian Pac J Cancer Prev. 2011;12(3):725-30
pubmed: 21627372
Obstet Gynecol. 2016 Oct;128(4):923-5
pubmed: 27661643
Gynecol Oncol Rep. 2017 Sep 28;22:58-63
pubmed: 29034308
BMC Cancer. 2018 Mar 6;18(1):208
pubmed: 29506486
Int J Cancer. 2010 Feb 15;126(4):976-84
pubmed: 19697326
J Gynecol Oncol. 2019 Mar;30(2):e17
pubmed: 30740950
Oncologist. 2015 Jun;20(6):627-34
pubmed: 25956407